Was Moderna Stock's 440% Surge Hiding In Plain Sight?

Today’s Stocks Money Markets Was Moderna Stock’s 440% Surge Hiding In Plain Sight? By Trefis Team , Contributor. Forbes contributors publish independent expert analyses and insights. Building a platform to do the job of 1 million analysts for Great Speculations Follow Author Aug 26, 2026, 11:02am EDT SHANGHAI, CHINA - AUGUST 21, 2026 - A netizen is using his mobilephone to view Moderna logo and using his computer to view Moderna webpage in Shanghai, China on August 21, 2026. (Photo credit should read CFOTO/Future Publishing via Getty Images) CFOTO/Future Publishing via Getty Images This article was written by Doug Nathman, with research by his team at Trefis. Moderna (MRNA) shares have surged over the past year, with the event that more than doubled its valuation in a single trading day occurring on August 19, 2026. On that date, Merck and Moderna announced that their Phase III melanoma trial of intismeran autogene in conjunction with KEYTRUDA had achieved its specified endpoints. Rather than focusing on what transpired on that specific day, the more pertinent question is what signs were observable beforehand. All of this information had been publicly available well prior to the readout, with some details dating back to early 2025. Enrollment Had Already Concluded For The Melanoma Trial By the time of its fourth-quarter 2024 report, Moderna had already communicated the crucial information: the Phase III adjuvant melanoma investigation involving intismeran, the personalized neoantigen treatment developed with Merck, was completely enrolled. This trial was among ten programs prioritized by the company for approval. A fully enrolled study no longer faces recruitment challenges; rather, it becomes a matter of counting participants and waiting for events to accumulate. The timing of its conclusion and the outcome remained uncertain. Cost Reductions And A Collaborator Covered The Wait The figures presented in the reports suggested a company under strain. As per its fiscal Q2 2025 results, the final quarterly report submitted before the surge commenced, trailing-twelve-month revenue was $3.06 billion , representing a 38.8% decline year over year, while the trailing operating margin was -107.1%. Alongside these results, Moderna announced it would be reducing its workforce by approximately 10%, and Merck was covering 50% of the expenses related to intismeran, as per management’s statements at that time, allowing the readout to be achieved without requiring total financial backing from the company. Options Traders Had Stopped Anticipating An Unusually Large Movement By August 8, 2025, implied volatility for Moderna had dropped to the 12th percentile of its trailing one-year range, a decline from the 34th percentile observed in early July 2025. A low percentile does not signal a bullish outlook; instead, it indicates that traders expected a smaller shift than what is typically seen, regardless of direction. The implied volatility was recorded at 56.9, with this percentile being calculated solely against the stock’s own historical performance over the past year. What The Indicators Could Convey Over the previous year, the stock yielded roughly 440%, in contrast to the approximately 21% return for the S&P 500. Pfizer saw an 18.4% increase while Alnylam Pharmaceuticals faced a 48.5% decrease in the same timeframe, indicating this was not a sector-wide reassessment. Following the melanoma data release, investors betting against the stock experienced unprecedented one-day losses . The indicators preceding the surge, all documented a year or more before the data arrived, outlined the nature of the risk rather than its outcome: enrollment had closed, funding was divided, and the market had ceased compensating for movements. The stock is currently priced around $145, at the higher end of its 52-week range of $22.36 to $174.38. Editorial Standards Reprints & Permissions LOADING VIDEO PLAYER... FORBES’ FEATURED Video Explore Topic